Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibody
J. Clin. Invest. Kelly R. Bales, et al. 116:825 doi:10.1172/JCI27120 [Go to this article.]

Figure 5
Hippocampal ACh release is unaltered after treatment with other IgGs. (A) Hippocampal release of ACh in WT and PDAPP transgenic mice following exposure to a novel environment and 24 hours after the administration of an irrelevant IgG (PDAPP + IgG; 500 μg i.p.) or the anti-Aβ antibody 3D6 (PDAPP + 3D6; 500 μg i.p.). (B) Release of ACh from the hippocampus of PDAPP and WT mice following administration of scopolamine (0.3 mg/kg i.p.) 24 hours after the administration of an irrelevant IgG or the anti-Aβ antibody 3D6. No significant difference between treated PDAPP and untreated PDAPP mice were observed in either A or B. (C) Basal levels of hippocampal ACh release from WT and PDAPP mice 24 hours following administration of an irrelevant IgG or the anti-Aβ antibody 3D6. *P < 0.05 versus WT and PDAPP + 3D6. n = 3–10 mice per group, 4–6 months of age.